The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

NICE issued a statement saying that a key uncertainty in estimating Enhertu’s cost-effectiveness was how much longer people on Enhertu live compared with those receiving standard treatment in ...

The agency said the two companies had failed to put forward "a cost-effective price that would have enabled us to recommend Enhertu as value for money for the taxpayer" in the final round of ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

The recommendation is based on a late-stage study that showed participants given Enhertu lived for a median ... Service — said it had not reached a cost-effective pricing agreement with ...

The amount spent on transgender treatments is close to what it would cost to supply all 1,000 women in England and Wales who would benefit from Enhertu, a drug that would give women with advanced ...

Cost of some cancer treatment can make it prohibitively ... Her only hope was a new toxic cancer drug called Enhertu – but it was found to be too expensive for the NHS to have.

An antibody-drug conjugate like Enhertu. However ... I am wondering how you are thinking about the total cost of that trial, and I know you did provide some sort of detail around timing.